Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ALT
ALT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALT News
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
Jan 29 2026
Newsfilter
Longevity Infrastructure Market Undergoes Structural Reset
Jan 29 2026
PRnewswire
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
Jan 29 2026
Newsfilter
Altimmune Announces $75 Million Stock Offering Amid Market Volatility
Jan 28 2026
Benzinga
Qorvo Shares Drop After Disappointing Earnings Guidance
Jan 28 2026
Benzinga
F5, Inc. Reports Strong Q1 Results and Raises FY26 Guidance
Jan 28 2026
Benzinga
Wall Street Optimistic Ahead of Fed Policy Decision
Jan 28 2026
stocktwits
Altimmune Secures $75M from Institutional Investor in Direct Offering
Jan 28 2026
seekingalpha
Altimmune Raises $75 Million to Fund MASH Trial Preparations
Jan 28 2026
stocktwits
Booz Allen Hamilton Q3 Earnings Beat Estimates, Shares Up 9.8%
Jan 23 2026
Benzinga
U.S. Government Requests Backup Power from Data Centers Amid Record Winter Storm
Jan 23 2026
stocktwits
Altimmune (ALT) Receives FDA Breakthrough Therapy Designation, Shares Rise Nearly 4%
Jan 22 2026
stocktwits
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
Jan 16 2026
seekingalpha
Altia Powers Cadillac Escalade IQ to Win 2026 MotorTrend SUV of the Year
Jan 06 2026
Globenewswire
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide, Significantly Improving Liver Health
Jan 06 2026
NASDAQ.COM
Altimmune (ALT) Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 16.9%
Jan 05 2026
Benzinga
Show More News
